Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 1
2003 1
2005 2
2006 2
2007 2
2008 1
2009 2
2010 1
2011 1
2012 4
2013 10
2014 15
2015 10
2016 7
2017 12
2018 5
2019 10
2020 9
2021 16
2022 7
2023 10
2024 12
2025 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

115 results

Results by year

Filters applied: . Clear all
Page 1
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.
Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P, Porta C, George S, Powles T, Donskov F, Neiman V, Kollmannsberger CK, Salman P, Gurney H, Hawkins R, Ravaud A, Grimm MO, Bracarda S, Barrios CH, Tomita Y, Castellano D, Rini BI, Chen AC, Mekan S, McHenry MB, Wind-Rotolo M, Doan J, Sharma P, Hammers HJ, Escudier B; CheckMate 214 Investigators. Motzer RJ, et al. N Engl J Med. 2018 Apr 5;378(14):1277-1290. doi: 10.1056/NEJMoa1712126. Epub 2018 Mar 21. N Engl J Med. 2018. PMID: 29562145 Free PMC article. Clinical Trial.
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.
Motzer R, Alekseev B, Rha SY, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Kopyltsov E, Méndez-Vidal MJ, Kozlov V, Alyasova A, Hong SH, Kapoor A, Alonso Gordoa T, Merchan JR, Winquist E, Maroto P, Goh JC, Kim M, Gurney H, Patel V, Peer A, Procopio G, Takagi T, Melichar B, Rolland F, De Giorgi U, Wong S, Bedke J, Schmidinger M, Dutcus CE, Smith AD, Dutta L, Mody K, Perini RF, Xing D, Choueiri TK; CLEAR Trial Investigators. Motzer R, et al. N Engl J Med. 2021 Apr 8;384(14):1289-1300. doi: 10.1056/NEJMoa2035716. Epub 2021 Feb 13. N Engl J Med. 2021. PMID: 33616314 Clinical Trial.
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.
Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J, Perez-Gracia JL, Dawson NA, van der Heijden MS, Dreicer R, Srinivas S, Retz MM, Joseph RW, Drakaki A, Vaishampayan UN, Sridhar SS, Quinn DI, Durán I, Shaffer DR, Eigl BJ, Grivas PD, Yu EY, Li S, Kadel EE 3rd, Boyd Z, Bourgon R, Hegde PS, Mariathasan S, Thåström A, Abidoye OO, Fine GD, Bajorin DF; IMvigor210 Study Group. Balar AV, et al. Among authors: vaishampayan un. Lancet. 2017 Jan 7;389(10064):67-76. doi: 10.1016/S0140-6736(16)32455-2. Epub 2016 Dec 8. Lancet. 2017. PMID: 27939400 Free PMC article. Clinical Trial.
Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1).
Vaishampayan UN, Muzaffar J, Winer I, Rosen SD, Hoimes CJ, Chauhan A, Spreafico A, Lewis KD, Bruno DS, Dumas O, McDermott DF, Strauss JF, Chu QS, Gilbert L, Chaudhry A, Calvo E, Dalal R, Boni V, Ernstoff MS, Velcheti V. Vaishampayan UN, et al. J Immunother Cancer. 2024 Nov 20;12(11):e010143. doi: 10.1136/jitc-2024-010143. J Immunother Cancer. 2024. PMID: 39567211 Free PMC article. Clinical Trial.
Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma.
Saliby RM, El Zarif T, Bakouny Z, Shah V, Xie W, Flippot R, Denize T, Kane MH, Madsen KN, Ficial M, Hirsch L, Wei XX, Steinharter JA, Harshman LC, Vaishampayan UN, Severgnini M, McDermott DF, Lee GM, Xu W, Van Allen EM, McGregor BA, Signoretti S, Choueiri TK, McKay RR, Braun DA. Saliby RM, et al. Among authors: vaishampayan un. Cancer Immunol Res. 2023 Aug 3;11(8):1114-1124. doi: 10.1158/2326-6066.CIR-22-0996. Cancer Immunol Res. 2023. PMID: 37279009 Free PMC article.
Race-Related Differences in Sipuleucel-T Response among Men with Metastatic Castrate-Resistant Prostate Cancer.
Heath EI, Thakur A, Chen W, Hwang C, Paller CJ, Cackowski FC, Boerner JL, Heilbrun L, Smith MP, Schalk DL, Schienschang A, Whitaker SA, Polend A, Smith D, Vaishampayan UN, Dickow B, Lum LG. Heath EI, et al. Among authors: vaishampayan un. Cancer Res Commun. 2024 Jul 1;4(7):1715-1725. doi: 10.1158/2767-9764.CRC-24-0112. Cancer Res Commun. 2024. PMID: 38856749 Free PMC article.
Impact of postprogression therapies on overall survival: Recommendations from the 2023 kidney cancer association think tank meeting.
Berg SA, La Rosa S, Zhang T, Pierorazio PM, Albiges L, Beckermann KE, Campbell MT, Carlo MI, Coleman K, George DJ, Geynisman DM, Johnson R, Jonasch E, Maranchie JK, McGregor BA, Shapiro DD, Singer EA, Shuch BM, Stadler WM, Tannir NM, Zakharia Y, Vaishampayan UN, Thall PF, Msaouel P. Berg SA, et al. Among authors: vaishampayan un. Urol Oncol. 2025 Mar;43(3):135-146. doi: 10.1016/j.urolonc.2024.10.022. Epub 2024 Nov 5. Urol Oncol. 2025. PMID: 39500687 Free article. Review.
Extragonadal germ cell tumors: A clinicopathologic study with emphasis on molecular features, clinical outcomes and associated secondary malignancies.
Abdulfatah E, Brown NA, Davenport MS, Reichert ZR, Camelo-Piragua S, Heider A, Huang T, Vaishampayan UN, Skala SL, Montgomery JS, Chinnaiyan AM, Kaffenberger SD, Bawa P, Shao L, Mehra R. Abdulfatah E, et al. Among authors: vaishampayan un. Hum Pathol. 2024 Jun;148:41-50. doi: 10.1016/j.humpath.2024.04.015. Epub 2024 Apr 30. Hum Pathol. 2024. PMID: 38697270
Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) Trial.
Lara PN Jr, Tangen C, Heath EI, Gulati S, Stein MN, Meng M, Alva AS, Pal SK, Puzanov I, Clark JI, Choueiri TK, Agarwal N, Uzzo R, Haas NB, Synold TW, Plets M, Vaishampayan UN, Shuch BM, Lerner S, Thompson IM Jr, Ryan CW. Lara PN Jr, et al. Among authors: vaishampayan un. Eur Urol. 2024 Sep;86(3):258-264. doi: 10.1016/j.eururo.2024.05.012. Epub 2024 May 29. Eur Urol. 2024. PMID: 38811313 Free PMC article. Clinical Trial.
115 results